NASDAQ OMX

Michael Phelps, World Champion Athlete and Mental Health Advocate, Appointed to Medibio Board of Directors

5.6.2017 12:00 | NASDAQ OMX

Dela

SYDNEY, Australia, June 05, 2017 (GLOBE NEWSWIRE) -- Medibio Limited (ASX:MEB) (MEB or the Company), an ASX listed medical technology company that has developed an effective objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders, today announces the appointment of Michael Phelps, the most decorated swimmer in history and Mental Health advocate, to the Board of Directors.

Since retiring from competitive swimming in 2016, Phelps has actively sought to raise awareness around mental health.  Prior to his appointment to Medibio's Board of Directors, Mr. Phelps worked with its team of world-class doctors and medical experts to explore ways in which Medibio's technology could help address the challenges associated with the identification and treatment of various mental health issues.  Mr. Phelps used Medibio's technology to analyze his own personal datasets and experienced firsthand how it is uniquely positioned to address the challenges associated with mental health diagnosis. 

"I am honored to accept this appointment because I have personally experienced Medibio's technology and believe it can help make a profound impact in diagnosing mental health and empowering people to seek the help and support they may need," said Phelps.  "In sports, there is so much focus on the physical aspects of performance, and athletes are analyzed from head to toe.  But for many athletes, mental health has not been a topic of focus, and the data analysis aspect of it has been missing up until now.  I personally suffered from mental health challenges from my teenage years on, and only fairly recently-after reaching a point of desperation-did I acquire the understanding, treatment, and support I needed, which has truly changed my life.  For me, self-awareness, from a mental health standpoint, is empowerment.  But I've seen firsthand-in sports and beyond-how difficult it is for people to understand, discuss, and confront stress, anxiety, and mental health concerns, all of which can seem like an insurmountable barrier to getting the help and support that is needed. I feel that the ease and objectivity with which Medibio's technology can accurately help to diagnose mental health will make a profound difference in people's lives. I want to help others who are dealing with these challenges and make the process for them to take action easier and more understandable."   

"We are thrilled to have Michael join our Board of Directors," said Jack Cosentino, Medibio Managing Director and CEO, "as a true champion of the mental health community.  His joining the Board of Directors brings recognition and validates the great need for objective mental health diagnosis that we offer through our industry-leading technology.  His lifelong dedication to excellence in the pool, his advocacy for mental health, and his understanding of data-driven solutions will provide a great addition to our Board. Michael's significant public profile will raise substantial awareness of mental health challenges and the real, tangible solutions that Medibio's diagnostics can provide." 

Widely regarded as one of the greatest athletes of all-time, Mr. Phelps has dedicated his time, fame, and focus to a number of philanthropic causes including water-safety, mental health, and anti-doping initiatives. His advocacy for mental health recently earned the recognition of the Substance Abuse and Mental Health Services Administration's ("SAMHSA") as the Honorary Chairperson of National Mental Health Awareness Day 2017 and recipient of the organizations Special Recognition Award. In addition, Mr. Phelps is an Ambassador for the Child Mind Institute's #MyYoungerSelf social media campaign in an effort to help end the stigmas associated with mental health and learning disorders.

Mr. Phelps established the Michael Phelps Foundation in 2008 with the focus on growing the sport of swimming and promoting healthy and active lifestyles, especially for children. The Foundation's signature program - im -  was developed in collaboration with KidsHealth.org and Michael Phelps Swimming to provide water-safety instruction, recreational pool activities, and swim training, as well as health, wellness, and goal-setting education.

In addition, Mr. Peter Carlisle, Managing Director of Octagon's Olympic and Action Sports division and Mr. Phelps' agent, will serve as an alternate Board Member.  Widely regarded as one of the most influential figures in the Olympic and action sports movements, Mr. Carlisle has dedicated his career to advocating for athletes and has witnessed firsthand the prevalence of mental health issues among elite athletes, the extent to which they are overlooked, and the profound need for increased awareness, education, treatment, and support. Prior to joining Octagon, he founded Carlisle Sports Management, a boutique Olympic and action sports representation agency, and served as an Attorney at Preti Flaherty. He earned his Juris Doctor from the University of Maine School of Law and Bachelor of Arts from Bates College.

Medibio Chairman Chris Indermaur said, "We sincerely welcome Michael and Peter to the board of Medibio and look forward to their contribution as the company continues to progress its unique mental illness diagnostic technology on many active pathways toward clinical and corporate validation. I am confident that this addition will be very warmly welcomed by all our shareholders."

In addition, the Company announces that it will seek to trade its stock in the U.S. using ticker symbol "MDBIF."  FINRA has allowed U.S. Canaccord Genuity Inc., as a market maker, to initiate a price quotation for the ticker symbol "MDBIF."  Medibio will seek to trade on the OTCQB Venture Market and will provide more information upon availability.

About Medibio Limited
Medibio (ASX:MEB), is an evidence-based medical technology company that has developed an objective test to assist in the diagnosis and management of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) panel circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental illness. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market.

 
Further Information: Website: www.medibio.com.au
U.S. Media Enquiries to:    
Nancy Thompson
Vorticom Inc.
nancyt@vorticom.com
T: + 1 (212) 532 2208
    Australian Media Enquiries:
Peter Taylor 
NWR Communications
peter@nwrcommunications.com.au 
T: +61 (0)412 036 231
       



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Minerva Neurosciences Announces Pricing of Public Offering of Common Stock29.6.2017 00:47Pressmeddelande

WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $7.75 per share. Proceeds to Minerva from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $38,750,000. The offering is expected to close on or about July 5th, 2017, subject to customary closing conditions. Citigroup and Jefferies are acting as the book-running managers for the offering, and JMP Securities is acting as lead manager for the offering.   Minerva has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock, on the same terms and conditions. Minerva intends to use the net proceeds from the offering, together with its existing cash and investments, to fund part of th

Yandy.com Celebrates Baywatch Movie With Inspired-By Swim Collection28.6.2017 20:18Pressmeddelande

Yandy launches swim collection for domestic and international consumers PHOENIX, June 28, 2017 (GLOBE NEWSWIRE) -- Yandy.com, the leading online retailer of intimates, swimwear, and specialty apparel, announced today the top-performing swimsuits from its Baywatch ®  swimwear collection. To celebrate the film's U.S. release - Yandy.com produced, marketed and sold three swimwear designs inspired by looks worn by the movie's female lifeguard characters. The new Baywatch movie follows devoted lifeguard Mitch Buchannon (Dwayne Johnson) as he butts heads with a brash new recruit (Zac Efron). Together, they uncover a local criminal plot that threatens the future of the Bay. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7d66d8a5-c973-4449-be85-6289c481671c Yandy's release of the Baywatch-inspired collection in May demonstrated an immediate interest among domestic consumers. No

Nasdaq's Directors Desk® and Boardvantage® to Introduce Board Assessments and Compliance Questionnaires28.6.2017 16:05Pressmeddelande

A Unique Collaboration between Nasdaq Corporate Solutions and the Center for Board Excellence NEW YORK and GREENSBORO, N.C., June 28, 2017 (GLOBE NEWSWIRE) -- Nasdaq Corporate Solutions, a business of Nasdaq, Inc. (Nasdaq:NDAQ), announced today a new partnership with The Center for Board Excellence (CBE), a provider of board assessments and compliance questionnaires. In the first phase of the partnership, Nasdaq Corporate Solutions will facilitate introductions for users of Directors Desk and Boardvantage - Nasdaq's board portal and meeting management solutions - to CBE's cloud-based corporate governance solutions including: board and committee assessments; director peer assessments; CEO and management evaluations; and directors' & officers' questionnaires. Later this year, the parties plan to offer an integrated workflow between Nasdaq's board portal solutions and CBE's EnGauge(TM) platform, making it even easier for users to elect to benefit fr

Datameer : Datameer Announces Industry-First Solution for Deploying AI to the Enterprise at Big Data Scale28.6.2017 15:00Pressmeddelande

New Datameer SmartAI democratizes data science within organizations by operationalizing deep learning models with enterprise scale and governance SAN FRANCISCO, June 28, 2017 (GLOBE NEWSWIRE) -- Furthering its mission to democratize data access within the enterprise, Datameer today unveiled SmartAI, an industry-first solution for operationalizing deep learning models directly within enterprise data lake environments securely and at scale. SmartAI finally allows enterprises to democratize data science, taking the deep learning work of data scientists from the lab to the business in production-ready scenarios that meet the big data security, governance and management standards IT requires. Now, business analysts can apply and execute trusted deep learning models against massive datasets from enterprise data lakes to drive better business outcomes. "With all the promise of data science and artificial intelligence, organizations have had difficulty delivering on its busi

Imperial Capital Hires Two Senior Sales Professionals Forming a Dedicated Convertible Institutional Sales Group28.6.2017 14:30Pressmeddelande

LOS ANGELES, June 28, 2017 (GLOBE NEWSWIRE) -- Imperial Capital Group, LLC ("Imperial Capital") announced today the hiring of James P. Kenney and Kevin Cadden, two senior institutional convertible sales professionals, forming a dedicated Convertible Sales Group, while adding to the franchise's continued credit sales & trading growth initiatives. The group will be responsible for expanding Imperial Capital's existing credit sales and trading business further into convertible products while working with a team of seasoned trading and research professionals to provide its institutional clients with valuable market color, trading ideas and excellent execution in both the fixed income and equity markets. "With the hiring of James and Kevin, we are able to provide our institutional clients with a team of veteran sales and trading professionals specializing in the convertible bond marketplace," said Tom Corcoran, President of Imperial Capital. "The team bri

AGF Management Limited Reports Strong Second Quarter 2017 Financial Results28.6.2017 14:00Pressmeddelande

30% growth in mutual fund gross sales compared to prior year quarter 50% of ranked AUM performed above median for the one-year period ended May 31, 2017, and 53% for the three-year period Achieved final close of InstarAGF Essential Infrastructure Fund (EIF) with $740 million in commitments Reported Diluted EPS of $0.16 compared to $0.12 in Q2 2016 TORONTO, June 28, 2017 (GLOBE NEWSWIRE) -- AGF Management Limited (AGF or the Company) today announced financial results for the second quarter ended May 31, 2017. Total assets under management (AUM) increased 8.0% to $36.4 billion compared to the same period in 2016, and up 3.7% compared to $35.1 billion as at February 28, 2017. AUM increased across all lines of business, including retail, private client, institutiona

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum